BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eli Lilly and Company (LLY) Release: Missouri Sees $7.7 Million In Mental Health Services Savings


10/19/2005 5:12:25 PM

JEFFERSON CITY, Mo., Dec. 9 /PRNewswire-FirstCall/ -- An innovative program to increase the quality of care that Missouri residents with severe mental illnesses receive while encouraging more efficient use of Medicaid dollars appears to have achieved both its goals, a recent analysis shows.

The Missouri Mental Health Medicaid Pharmacy Partnership Program (MHMPP), the first program of its kind in the United States, evaluates Medicaid mental health prescribing practices. The program seeks to improve care for Missouri residents by educating doctors about evidence-based best practices for mental health medications and reducing inefficient and ineffective prescribing patterns.

"Not only did the MHMPP program positively affect the quality of care received by Missourians suffering from severe mental illness, it also allowed Missouri to save $7.7 million in costs the Medicaid program would have incurred in state fiscal year 2004 had the inefficient prescribing patterns not been identified," said Joseph Parks, M.D., medical director of the Department of Mental Health.

"We were pleased to see that most Missouri doctors are following the recommended guidelines when prescribing medications. We have identified the small number of doctors who aren't and are reaching them with educational materials to help change their prescribing habits. These changes have resulted in better patient care and savings for our Medicaid program," said Parks.

Some of the inefficient prescribing patterns the program identifies include: duplicative prescribing of medication by different doctors for the same patient; prescribing multiple medications from the same therapeutic class; children on three or more psychotropic medications; and premature, rapid switching from one medication to another.

After reviewing, identifying and analyzing problematic prescribing patterns, the program provides doctors deviating from best practices with information to help them make patient care decisions based on the latest medical evidence.

The MHMPP program is entirely voluntary for Missouri doctors. All decisions regarding treatment and medications are made privately between the physician and the patient and are completely individualized.

An analysis from the program's first year shows:

* 98 percent reduction of patients who are prescribed the same mental health medications from multiple doctors;

* 64 percent reduction of patients who are on two or more mental health medications of the same type;

* 43 percent reduction of children on three or more psychotropic medications; and

* 40 percent reduction of patients receiving an unusually high dosage of medication.

The MHMPP was developed by the Missouri Department of Mental Health and Missouri Department of Social Services, Division of Medical Services, in collaboration with Comprehensive NeuroScience, Inc. Eli Lilly and Company, an Indianapolis-based pharmaceutical company, has been providing financial support for this program in an effort to promote excellence in patient health care.

"The program is a model of cooperation among state agencies. It represents a collaboration of the clinical resources of our staffs, the industry and our providers. Most importantly, it assures our most vulnerable citizens the greatest access to best medical practices and current therapies, while being sensitive to our limited resources," said Christine Rackers, director of the Missouri Department of Social Services, Division of Medical Services.

The program also has proven to be popular outside of Missouri. Fifteen other states have signed contracts to develop similar programs, buoyed by the increasing awareness that mental health is integral to physical health. This project demonstrates two traits other states are eager to copy:

* That management of mental health drugs should be based on nationally recognized standards and guidelines, as well as individual patient needs, to ensure the highest quality care; and

* That Medicaid dollars for mental health drugs can be wisely managed by focusing directly on the quality of prescribing practices.

"We fully support cost-effective programs like this that focus on improving patient care while encouraging more efficient use of taxpayer dollars," said Jack Bailey, Lilly vice president, Business to Business. "We believe a significant opportunity exists within the Medicaid system to reduce costs by improving the quality of care and patient outcomes, and we applaud Missouri's leadership and innovation with this project."

For more information on this project, visit the DMH Web site at http://www.dmh.missouri.gov/index.htm and DMS at http://www.dss.state.mo.us/dms .

O-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20041209/DMHLOGO )

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20041209/DMHLOGOPRN Photo Desk, photodesk@prnewswire.comMissouri Department of Mental Health

CONTACT: Janice Chavers of Eli Lilly and Company, +1-317-651-6253,chaversjm@lilly.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES